Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CelliStem®OA-sEV in moderate knee osteoarthritis
NCT05060107Phase 1Unknown
- Start
- Oct 2021
- Primary completion
- Apr 2023
- Modality
- Lipid-based Nanoparticles
01
Overview
Phase 1, open-label, single-arm trial of CelliStem OA-sEV in osteoarthritis (OA). Primary endpoint: Adverse Event at 12 months. Status: unknown.
02
Drugs
CelliStem OA-sEV
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05060107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060107.